Business Wire

Nordtreat Has Appointed Outi Kallio as the New CEO

3.9.2024 07:50:00 EEST | Business Wire | Press release

Share

The Finnish technology company Nordtreat strengthens its growth by appointing Outi Kallio as the new CEO. Her era at Nordtreat will start from the turn of 2024/2025. Outi Kallio has a wealth of experience in commercial and industrial management, having held several key positions at Teknos Group.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240902513997/en/

The Finnish technology company Nordtreat strengthens its growth by appointing Outi Kallio as the new CEO. (Photo: Business Wire)

Outi Kallio has an extensive background in sales, HR, and marketing. She also has a proven track record of leading international teams. Currently, she holds the position of Global Commercial Director at Teknos Group.

"As Nordtreat continues to grow and evolve, we are thrilled to welcome Outi Kallio as our new CEO. Her diverse experience and proven leadership skills make her the ideal candidate to lead Nordtreat into its next chapter. We believe that Outi Kallio’s strategic vision and operational expertise will drive our company forward and enhance shareholder value," says Leif Frilund, Chairman of the Board of Nordtreat.

"With over a decade of experience in the coatings industry, I have seen a growing shift towards sustainable solutions, driven by increasing customer expectations. Nordtreat's commitment to bio-based technologies and its strong ethos of responsibility provides a solid foundation for scaling Finnish sustainability expertise into an international growth story. I am excited to join this team of top professionals and look forward to contributing to our shared success," Outi Kallio says.

As Nordtreat’s CEO, Outi Kallio will succeed Aki Borgentorp, who has led the company for ten years. These years have included the development of the first truly bio-based flame retardant for wood-based materials and the growth of a worldwide market presence.

"Over the past decade, Nordtreat has built a scalable platform for the development and production of bio-based flame retardants for wood-based materials. I am convinced that under Outi Kallio’s leadership, Nordtreat will continue to innovate and expand its presence in the market and make a significant impact in the construction materials industry," says Aki Borgentorp.

"On behalf of the Nordtreat board, I’d like to express our sincere gratitude to Aki Borgentorp for his remarkable achievement in building Nordtreat from scratch into a leading provider of new sustainable flame-retardant solutions. We wish Aki the best of success in his future endeavours," Leif Frilund says.

Nordtreat has also welcomed Dr Thomas Kostka, the Head of Corporate Venturing at Altana AG, to join the board of directors starting in August 2024. Additionally, Nordtreat has appointed Sakari Saarela, a partner in the UB FIGG Fund, as a board observer. Sampsa Auvinen, who has been on Nordtreat's board since 2022, will continue as UB FIGG's representative on the board. Sampsa Auvinen is also the Chairman of the Advisory Board of UB FIGG. Altana Group, the global leader in true specialty chemicals, and the Finnish sustainability fund UB Forest Industry Green Growth Fund (UB FIGG), a growth private equity fund investing in sustainable and resource-efficient forest and bio-based industries, announced an investment in Nordtreat in June 2024.

"We are happy to welcome Thomas Kostka to the board of directors at Nordtreat. He brings us a deep understanding of the industry and strategic insights that will be invaluable as we continue to grow," says Leif Frilund.

Image folder

Nordtreat is a Finnish technology company founded in 2015, specializing in the development and production of environmentally friendly, high-performance flame retardants. Utilizing bio-based raw materials, Nordtreat's products comply with the latest fire protection regulations and have been used to protect over 2000 buildings worldwide. The company's flagship technology, NORFLAM®, is designed to provide superior fire protection while maintaining environmental sustainability. Nordtreat's innovative solutions are aimed at meeting the growing global demand for safer, more sustainable construction materials. www.nordtreat.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240902513997/en/

Contacts

Leif Frilund
Chairman, Nordtreat
leif.frilund@walki.com
+358403543330

Aki Borgentorp
CEO, Nordtreat
aki.borgentorp@nordtreat.com
+358 400 366801

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on CASGEVY ® , Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions11.6.2026 09:01:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent patients. These data were presented at the European Hematology Association (EHA) Congress and simultaneously published in the New England Journal of Medicine (NEJM). “The data presented at EHA and published in NEJM underscore the consistent, durable and transformative benefits CASGEVY can provide to people living with sickle cell disease or transfusion-dependent beta thalassemia from early in life,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Off

PUMA Brings NITRO™ to Football With the PUMA NITRO Lab in Los Angeles11.6.2026 09:00:00 EEST | Press release

Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and NITRO™'s arrival in football for the first time on a football boot. Previous editions of the NITRO™ Lab in Paris, Tokyo, and London explored the future of running performance and cemented NITRO™ as the defining technology in elite running with Fast-R3. Now, with the world’s attention turning to football, Los Angeles is where that journey takes its next step, introducing the same innovation DNA that reshaped the track to the pitch, when it matters most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610728823/en/ Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and N

AHS Properties Acquires Shangri-La Hotel for AED 1.1 Billion in Landmark Sheikh Zayed Road Transaction11.6.2026 09:00:00 EEST | Press release

AHS Properties today announced the acquisition of Shangri-La Hotel for AED 1.1 billion, one of the largest single-asset real estate transactions recorded in recent history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605096792/en/ Shangri-La Hotel Exterior, Sheikh Zayed Road. (Photo: AETOSWire) Acquired from Mismak Asset Management, the transaction cements one of the most concentrated private-sector bets on Sheikh Zayed Road's next decade. The Shangri-La Hotel is a 43-floor, 200-metre tower on Sheikh Zayed Road, and was one of the first five-star hotels to open on the corridor when it was completed in 2003. The acquisition adds an iconic anchor asset to a portfolio that already includes AHS Tower, a recently sold-out Grade-A commercial development on Sheikh Zayed Road, and AHS City, the developer’s flagship master-planned, mixed-use community on the corridor with a forecast gross development value of AED 25 billion. To

Curatis Increases Revenue Growth Guidance for 202611.6.2026 08:00:00 EEST | Press release

Curatis Holding AG (SIX: CURN) increases its revenue growth guidance for the financial year 2026: the company is forecasting a revenue growth of approximately 40% in 2026, in contrast to the previous outlook of over 25%. Based on preliminary figures for the first five months of 2026, Curatis expects a significantly higher than anticipated revenue growth for 2026. This growth is driven by products that Curatis has marketed for some time, as well as by products added to its portfolio in 2025 and 2026. Under the new guidance, Curatis projects revenues of approximately CHF 15m in 2026, up from CHF 10.8m in 2025. Curatis will publish detailed financial figures for the first six months of 2026 in the half-year report on 21 September 2026. About Curatis Curatis Holding AG is a publicly listed company (CURN.SW) focused on the late stage development and commercialization of drugs for rare diseases and specialty care. Curatis has a sales portfolio of more than 40 products and a pipeline of orpha

Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments11.6.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the largest of its kind – exploring the evolving expectations and experiences of patients and HCPs with anti-wrinkle aesthetic treatments. As the dermatology category leader, this survey demonstrates Galderma’s commitment to advancing progress in this market, through robust clinical research, product performance, and practitioner support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610228460/en/ Anti-wrinkle treatments are among the most established procedures in aesthetic medicine and currently represent the most commonly performed nonsurgical cosmetic treatment worldwide.2 The market is set to expand further, with 85% of surveyed patients globally indicating they plan to maintain or increase their use in the future, including 97% in China and 87% in the UK.2

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye